AbbVie, Bristol-Myers Squibb, Eli Lilly, and AstraZeneca participated in drug delivery innovation discussions and partnerships.

The entities involved

• AbbVie →

  pharmaceutical company

  • Market competition driven by AI and rising Treasury yields is causing market volatility involving AbbVie, Bank of America, Adobe, and Accenture.12:59
  • Fed rate hike drove up fixed-income yields, highlighting AbbVie and Johnson & Johnson as large dividend-paying pharmaceutical companies.Mon 19:12
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Gardiner Harris's investigative reporting led to fraud fines against Bristol-Myers Squibb and a book dissecting Johnson & Johnson scandals.Tue 01:35
  • Dean Hakanson led U.S. Medical Affairs for the remdesivir launch and served in senior leadership positions at major pharmaceutical companies.Mon 17:32
• Eli Lilly and Company →

  American pharmaceutical company

  • Lilly Canada sponsored an innovation challenge while HealthCareCAN highlighted access barriers in Canada.Tue 20:20
  • Houthis actions and Iran's geopolitical moves are elevating gas prices, prompting investors to rotate into safer, low-growth sectors.Mon 15:45

Related events

• AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.Jun 8
• AstraZeneca sought a mega-merger with a US rival, adding a specific development to the ongoing talks with Bristol-Myers Squibb.Aug 9
• Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.Oct 21
• AbbVie, Johnson & Johnson, Bristol-Myers Squibb, and Amgen are innovating targeted, cost-effective therapies for psoriatic arthritis.Jun 8
• Eli Lilly and Company and BeOne Medicines Ltd. are both identified as major players in the medical sector.Oct 16